Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

288 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Early bronchodilator action of glycopyrronium versus tiotropium in moderate-to-severe COPD patients: a cross-over blinded randomized study (Symptoms and Pulmonary function in the moRnING).
Marin JM, Beeh KM, Clemens A, Castellani W, Schaper L, Saralaya D, Gunstone A, Casamor R, Kostikas K, Aalamian-Mattheis M. Marin JM, et al. Among authors: kostikas k. Int J Chron Obstruct Pulmon Dis. 2016 Jun 28;11:1425-34. doi: 10.2147/COPD.S106127. eCollection 2016. Int J Chron Obstruct Pulmon Dis. 2016. PMID: 27418815 Free PMC article. Clinical Trial.
The effect of indacaterol/glycopyrronium versus tiotropium or salmeterol/fluticasone on the prevention of clinically important deterioration in COPD.
Anzueto AR, Vogelmeier CF, Kostikas K, Mezzi K, Fucile S, Bader G, Shen S, Banerji D, Fogel R. Anzueto AR, et al. Among authors: kostikas k. Int J Chron Obstruct Pulmon Dis. 2017 May 4;12:1325-1337. doi: 10.2147/COPD.S133307. eCollection 2017. Int J Chron Obstruct Pulmon Dis. 2017. PMID: 28496316 Free PMC article.
Exacerbation heterogeneity in COPD: subgroup analyses from the FLAME study.
Vogelmeier CF, Chapman KR, Miravitlles M, Roche N, Vestbo J, Thach C, Banerji D, Fogel R, Patalano F, Olsson P, Kostikas K, Wedzicha JA. Vogelmeier CF, et al. Among authors: kostikas k. Int J Chron Obstruct Pulmon Dis. 2018 Apr 10;13:1125-1134. doi: 10.2147/COPD.S160011. eCollection 2018. Int J Chron Obstruct Pulmon Dis. 2018. PMID: 29692607 Free PMC article. Clinical Trial.
Indacaterol/glycopyrronium reduces the risk of clinically important deterioration after direct switch from baseline therapies in patients with moderate COPD: a post hoc analysis of the CRYSTAL study.
Greulich T, Kostikas K, Gaga M, Aalamian-Mattheis M, Lossi NS, Patalano F, Nunez X, Pagano VA, Fogel R, Vogelmeier CF, Clemens A. Greulich T, et al. Among authors: kostikas k. Int J Chron Obstruct Pulmon Dis. 2018 Apr 16;13:1229-1237. doi: 10.2147/COPD.S159732. eCollection 2018. Int J Chron Obstruct Pulmon Dis. 2018. PMID: 29713156 Free PMC article. Clinical Trial.
288 results